Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000199126 | SCV000252046 | pathogenic | not provided | 2013-06-04 | criteria provided, single submitter | clinical testing | c.1142_1145dupATCA: p.Trp383SerfsX6 (W383SfsX6) in exon 11 of the PDHA1 gene (NM_000284.3). The normal sequence with the bases that are duplicated in braces is: GCCA{ATCA}GTGG. The c.1142_1145dupATCA mutation in the PDHA1 gene has been reported previously in association with pyruvate dehydrogenase complex (PDHc) deficiency (Endo et al., 1991). The duplication causes a frameshift starting with codon Tryptophan 383, changes this amino acid to a Serine residue and creates a premature Stop codon at position 6 of the new reading frame, denoted p.Trp383SerfsX6. This mutation is predicted to cause loss of normal protein function through protein truncation. The variant is found in MITONUC-MITOP panel(s). |
Ambry Genetics | RCV000624104 | SCV000742395 | pathogenic | Inborn genetic diseases | 2017-05-11 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000199126 | SCV001249126 | pathogenic | not provided | 2020-06-01 | criteria provided, single submitter | clinical testing | |
Illumina Clinical Services Laboratory, |
RCV000011627 | SCV001251622 | pathogenic | Pyruvate dehydrogenase E1-alpha deficiency | 2020-02-04 | criteria provided, single submitter | clinical testing | The PDHA1 c.1142_1145dupATCA (p.Trp383SerfsTer6) variant results in a frameshift and is predicted to result in premature termination of the protein. Across a selection of the available literature, the p.Trp383SerfsTer6 variant has been identified in at least 10 individuals in a heterozygous state with variable phenotypes related to pyruvate dehydrogenase deficiency. Phenotypes include brain abnormalities (thin corpus callosum, cerebral atrophy, or cerebellar malformations), microcephaly, intellectual disability, hypotonia, elevated lactate and pyruvate levels, and epilepsy (Endo et al. 1991; Lissens et al. 2000; Quintata et al. 2010; DeBrosse et al. 2012). At least four of these individuals carried the p.Trp383SerfsTer6 variant in a de novo state (Lissens et al. 2000; Quintata et al. 2010). Evaluation of patient fibroblasts showed significantly decreased pyruvate dehydrogenase complex and pyruvate dehydrogenase E1 activity levels compared to controls (Endo et al. 1991; Lissens et al. 2000; Quintata et al. 2010). The p.Trp383SerfsTer6 variant is not found in the Genome Aggregation Database and is in a region of good sequencing coverage, so the variant is presumed to be rare. This variant occurs in the last exon and may escape nonsense mediated decay. Based on the collective evidence, the p.Trp383SerfsTer6 variant is classified as pathogenic for pyruvate dehydrogenase deficiency. |
Hudson |
RCV000011627 | SCV001364304 | pathogenic | Pyruvate dehydrogenase E1-alpha deficiency | 2020-05-15 | criteria provided, single submitter | research | ACMG codes: PVS1, PS2, PS4M, PM2, PP5 |
OMIM | RCV000011627 | SCV000031859 | pathogenic | Pyruvate dehydrogenase E1-alpha deficiency | 1993-04-01 | no assertion criteria provided | literature only | |
Biochemical Molecular Genetic Laboratory, |
RCV000011627 | SCV001133088 | likely pathogenic | Pyruvate dehydrogenase E1-alpha deficiency | 2019-09-26 | no assertion criteria provided | clinical testing |